Navigation Links
Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/6/2008

X-004 in reducing the symptoms of obsessive-compulsive disorder. Results for both trials are expected in the second half of 2009.

-- In addition, the USPTO issued U.S. Patent No. 7,425,571 providing broad coverage of the use of zonisamide either alone or in combination with other drugs for the treatment of obesity through 2023. The USPTO has also issued U.S. Patent No. 7,429,580 which broadly covers zonisamide in combination with various marketed atypical antipsychotics through 2025. Orexigen has licensed both patents on an exclusive basis from Duke University.

The Company also made a number of important presentations of data at the recent Annual Scientific Meeting of the Obesity Society. These included the following:

-- Presented data related to the impact on tolerability of naltrexone in an SR form, as compared to an earlier immediate release (IR) form. In two Phase 1 trials, Contrave utilizing the SR formulation of naltrexone successfully achieved key objectives (lowered naltrexone Cmax, increased Tmax, comparable AUC). Additionally, preliminary analysis of blinded data from nearly 4,000 patients participating in a series of four ongoing Phase 3 trials supports that the naltrexone SR formulation may be associated with tolerability advantages.

-- Summarized the impact of Contrave in the NB-201 Phase 2b trial on various markers of metabolic and cardiovascular risk. This review demonstrated that Contrave made a positive impact on HDL cholesterol, insulin and fasting glucose, as well as waist circumference. In addition, among Contrave patients who completed 24 weeks of treatment, the proportion of subjects with metabolic syndrome decreased from 31% to 15%. More than 47 million Americans have metabolic syndrome, a condition associated with increased risk of diabetes and cardiovascular disease.

-- Presented in oral and poster presentations data from the Phase 2b trial of Empatic, ZB-201. In this trial, Empatic demonstrated up to 15% r
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
5. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
6. CV Therapeutics Reports 2008 Third Quarter Financial Results
7. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
8. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
9. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 Bipartisan passage this ... bill designed to stimulate development and commercialization of new ... praised by leaders of SPIE, the international society ... American Manufacturing and Innovation (RAMI) Act, now moves to ... have said they are optimistic that it will win ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
Breaking Biology Technology:House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3POCT Market in China 2014-2018 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... - Only Nasal Powder Bird Flu Vaccine Under Development ... No Preservatives - Stable at Room Temperature For 3 Years; No Cold Chain ... ... Bulletin Board: CARN) today announced that its,wholly-owned subsidiary DelSite Biotechnologies, Inc. received a shipment,of ...
... Visits Each Year, East Coast,s Largest Independent Clinical ... ... CEDAR KNOLLS, N.J., Feb. 14 MedeFile,International, Inc. ... medical records management solutions, today announced,that it has signed ...
... Shenzhen Beike,Biotechnology Co., Ltd. ( http://www.beikebiotech.com ... cord stem cells to successfully treat a variety ... Mayor of,Manchester, has returned today to the United ... life-threatening condition known as,cerebellar atrophy. As the latest ...
Cached Biology Technology:Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 2Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 3Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration 4Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 2Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility 3
(Date:9/18/2014)... is stored in DNA, tiny strands of nucleic acid ... To express this genetic data, our DNA is copied ... proteins that perform tasks in our cells. , ... RNA molecule. Unlike all other known RNAs, this molecule ... molecules are abundant, little has been known about how ...
(Date:9/18/2014)... Dogs generally seem to be cheerful, happy-go-lucky characters, so ... outlook on life. , In fact some dogs ... University of Sydney shows. , "This research is ... in dogs objectively and non-invasively. It offers researchers and ... and how that changes," said Dr Melissa Starling, from ...
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Dogs can be pessimists too 2Dogs can be pessimists too 3Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... a new synthetic metabolic pathway for breaking down glucose that ... of biofuels. The new pathway is intended ... series of chemical reactions that nearly all organisms use to ... converts four of the six carbon atoms found in glucose ...
... NASA,s Cassini spacecraft has detected propylene, a chemical used ... products, on Saturn,s moon Titan. This is the ... moon or planet, other than Earth. A small ... by Cassini,s Composite Infrared Spectrometer (CIRS). This instrument measures ...
... 30, 2013 UC Irvine scientists Aaron Esser-Kahn, Sunil ... the prestigious 2013 National Institutes of Health Director,s New ... projects by early-career researchers that show potential to transform ... new ways to improve human health. Esser-Kahn, Gandhi ...
Cached Biology News:UCLA engineers develop new metabolic pathway to more efficiently convert sugars into biofuels 2NASA's Cassini spacecraft finds ingredient of household plastic in space 2UCI achieves rare trifecta: 3 scientists receive New Innovator Awards 2
Request Info...
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
...
Biology Products: